Friday 16 October 2026
Export ZNTL’s income statement to Excel — free account
Zentalis Pharmaceuticals, Inc.
ZNTL Healthcare Biotechnology
Zentalis Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $67.4 million. In the quarter to June 2026, EPS fell 59.5% and free cash flow fell 9.06%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.13
0.11
−4.91%
Follow ZNTL
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 22.00 | 34.48 | 17.33 | 9.56 | 2.66 | 1.01 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 61.29 | 87.19 | 84.14 | 31.46 | 18.07 | 3.33 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 62 | 124 | 177 | 156 | 168 | 166 | 106 | ||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.41 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | 0 | — | — | — | — | — | 67 | — | ||||
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 100.00 | — | |||||
| EBT | — | — | (23) | (46) | (118) | (165) | (221) | (277) | (166) | (137) | |||||
| EBT margin, % | — | — | (168,550.36) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (245.74) | 0.00 | |||||
| Net income | — | 0 | (21) | (46) | (119) | (166) | (237) | (292) | (166) | (137) | |||||
| Depreciation | — | — | 0 | 0 | 1 | 1 | (2) | (12) | (3) | (2) | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.95 | 0.00 | ||||
| Earnings | — | — | (0.59) | (8.29) | (4.19) | (3.72) | (4.48) | (4.47) | (2.33) | (1.91) | |||||
| Cash flow | — | — | (0.68) | (6.99) | (3.09) | (3.61) | (3.10) | (3.18) | (2.40) | (1.74) | |||||
| Capex | — | — | 0.00 | (0.06) | (0.03) | (0.14) | (0.05) | (0.01) | 0.00 | 0.01 | |||||
| Free cash flow | — | — | (0.68) | (7.06) | (3.12) | (3.75) | (3.15) | (3.19) | (2.41) | (1.73) | |||||
| Book value | — | — | 0.69 | (13.09) | 11.86 | 8.54 | 8.21 | 6.69 | 4.74 | 3.01 | |||||
| Shares, m | — | — | 36 | 6 | 28 | 43 | 53 | 65 | 71 | 72 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | — | — | — | — | — | 0.00 | — | ||||
| P/S | — | — | 0.00 | — | — | — | — | — | 0.00 | — | |||||
| P/B | — | — | 0.00 | — | — | — | — | — | 0.64 | — | |||||
| EV/Sales | — | — | 0.00 | — | — | — | — | — | 0.00 | — | |||||
| EV/FCF | — | — | (1.40) | — | — | — | — | — | 0.91 | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (24) | (39) | (87) | (154) | (164) | (208) | (171) | (125) | ||||
| Capex | — | — | 0 | 0 | (1) | (6) | (3) | (1) | 0 | 1 | |||||
| Free cash flow | — | — | (24) | (39) | (88) | (160) | (166) | (208) | (171) | (125) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 20 | 54 | 317 | 307 | 395 | 427 | 333 | 217 | ||||
| Total debt | — | — | — | 2 | 2 | 46 | 47 | — | — | — | |||||
| Net debt | — | — | (25) | (67) | (339) | (340) | (437) | (483) | (371) | (246) | |||||
| Shareholders’ equity | — | — | 25 | (73) | 333 | 364 | 434 | 437 | 337 | 216 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (102.65) | (71.06) | (52.02) | (38.71) | (47.66) | (53.56) | (33.77) | (38.11) | ||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | (550.27) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | 36.59 | 84.29 | (90.61) | (45.49) | (59.31) | (67.06) | (42.82) | (49.53) | |||||
Negative figures in brackets.
Fiscal years to Dec 2024 · latest quarter Dec 2024
Charts ten years each
Zentalis Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LXEO Lexeo Therapeutics, Inc. | $226.6M | — (loss-making) | — (loss-making) | — | n/m | +35.58% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PLX Protalix BioTherapeutics, Inc. | $217.5M | 11.4× | 10.2× | +27.07% (above 0%: growing) | +2,280.95% (above 0%: growing) | −94.09% (below 0%: shrinking) | 60.99% | 23.48% | Compare |
| CAMP CAMP4 Therapeutics Corporation | $216.5M | — (loss-making) | — (loss-making) | +18.84% (above 0%: growing) | n/m | −23.90% (below 0%: shrinking) | 100.00% | (752.11%) | Compare |
| PYXS Pyxis Oncology, Inc. | $215.3M | — (loss-making) | — (loss-making) | — | n/m | −5.46% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| EVMN Evommune Inc. | $215.2M | — (loss-making) | — (loss-making) | — | n/m | +21.78% (above 0%: growing) | 100.00% | 0.00% | Compare |
| MGNX MacroGenics, Inc. | $214.7M | — (loss-making) | — (loss-making) | +377.97% (above 0%: growing) | n/m | +12.88% (above 0%: growing) | 100.00% | (42.19%) | Compare |
| ZNTL Zentalis Pharmaceuticals, Inc. | $212.1M | — (loss-making) | — (loss-making) | — | n/m | −9.06% (below 0%: shrinking) | 100.00% | 0.00% | |
| LRMR Larimar Therapeutics, Inc. | $206.7M | — (loss-making) | — | — | n/m | −127.63% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ADCT ADC Therapeutics SA | $190.2M | — (loss-making) | — (loss-making) | +2.17% (above 0%: growing) | n/m | +50.98% (above 0%: growing) | 87.80% | (132.03%) | Compare |
| Median of peers | $215.2M | — | — | +22.96% | — | +3.71% | 93.90% | 0.00% |
Zentalis Pharmaceuticals, Inc. (ZNTL) key facts
- Zentalis Pharmaceuticals, Inc. (ZNTL) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Zentalis Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $67.4 million.
- As of October 16, 2026, ZNTL traded at $2.22, a market capitalization of $212.1 million.
- Return on equity was −49.5% and debt-to-equity 0.00.
- Its Altman Z-score is −2.42 (distress zone) for fiscal 2024.